HUE053354T2 - Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények - Google Patents

Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUE053354T2
HUE053354T2 HUE17747622A HUE17747622A HUE053354T2 HU E053354 T2 HUE053354 T2 HU E053354T2 HU E17747622 A HUE17747622 A HU E17747622A HU E17747622 A HUE17747622 A HU E17747622A HU E053354 T2 HUE053354 T2 HU E053354T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
containing same
sulfonamide derivative
sulfonamide
Prior art date
Application number
HUE17747622A
Other languages
English (en)
Inventor
Munetaka Tokumasu
Masatsugu Noguchi
Mizuki Kawahira
Kana Iwasaki
Nobuhiko Hayakawa
Wataru Miyanaga
Yuki Saitou
Yui YAMAURA
Ayatoshi Ando
Atsushi Tsuruta
Misato Noguchi
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of HUE053354T2 publication Critical patent/HUE053354T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
HUE17747622A 2016-02-05 2017-02-06 Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények HUE053354T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016021053 2016-02-05

Publications (1)

Publication Number Publication Date
HUE053354T2 true HUE053354T2 (hu) 2021-06-28

Family

ID=59500204

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17747622A HUE053354T2 (hu) 2016-02-05 2017-02-06 Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények

Country Status (16)

Country Link
US (1) US10562898B2 (hu)
EP (1) EP3412660B9 (hu)
JP (1) JP6820282B2 (hu)
KR (1) KR20180104758A (hu)
CN (1) CN108699008B (hu)
AU (1) AU2017214589B2 (hu)
CA (1) CA3013433A1 (hu)
DK (1) DK3412660T3 (hu)
EA (1) EA036432B1 (hu)
ES (1) ES2856125T3 (hu)
HU (1) HUE053354T2 (hu)
MX (1) MX2018009459A (hu)
PL (1) PL3412660T3 (hu)
PT (1) PT3412660T (hu)
TW (1) TWI730042B (hu)
WO (1) WO2017135472A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142824A0 (en) 1998-10-26 2002-03-10 Univ New York State Res Found Lipoic acid derivatives and their use in treatment of disease
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2023058645A1 (ja) * 2021-10-05 2023-04-13 Eaファーマ株式会社 化合物又はその薬学的に許容される塩の製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
PT1244625E (pt) 1999-12-06 2005-09-30 Hoffmann La Roche 4-piridinil-n-acil-l-fenilalaninas
WO2001056994A1 (en) * 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
EP1288205B1 (en) 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
JP2007526230A (ja) 2003-06-25 2007-09-13 エラン ファーマシューティカルズ,インコーポレイテッド 関節リウマチを治療する方法および組成物
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
US20050192279A1 (en) 2004-02-10 2005-09-01 Kent Barbay Pyridazinones as antagonists of alpha4 integrins
CN101005854A (zh) 2004-04-16 2007-07-25 健泰科生物技术公司 用于增进b细胞消除的方法
AU2006251620B8 (en) 2005-05-20 2013-07-18 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives as VLA-4 antagonists
ES2609524T3 (es) 2012-04-24 2017-04-20 Ea Pharma Co., Ltd. Derivado se sulfonamida y uso medicinal del mismo
DE102013206014A1 (de) * 2013-04-05 2014-10-09 Dürr Systems GmbH Energiewandler-System und Baugruppen hierfür
EP3064491B1 (en) 2013-10-29 2020-01-08 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof

Also Published As

Publication number Publication date
EP3412660B1 (en) 2020-11-18
JP6820282B2 (ja) 2021-01-27
CN108699008B (zh) 2021-10-08
WO2017135472A1 (ja) 2017-08-10
CA3013433A1 (en) 2017-08-10
CN108699008A (zh) 2018-10-23
JPWO2017135472A1 (ja) 2018-11-29
TW201733991A (zh) 2017-10-01
TWI730042B (zh) 2021-06-11
ES2856125T3 (es) 2021-09-27
AU2017214589B2 (en) 2020-09-03
US10562898B2 (en) 2020-02-18
KR20180104758A (ko) 2018-09-21
DK3412660T3 (da) 2020-11-30
US20190040059A1 (en) 2019-02-07
BR112018015855A2 (pt) 2018-12-26
EP3412660A1 (en) 2018-12-12
MX2018009459A (es) 2018-09-21
PL3412660T3 (pl) 2021-04-19
AU2017214589A1 (en) 2018-08-16
EP3412660B9 (en) 2021-04-14
EA036432B1 (ru) 2020-11-10
EA201891780A1 (ru) 2019-02-28
PT3412660T (pt) 2021-01-13
EP3412660A4 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
HK1259145A1 (zh) 3-脫氧衍生物及其藥物組合物
IL265360B (en) Pharmaceutical composition
HK1251153A1 (zh) 一種藥物組合物及其應用
HUE053354T2 (hu) Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL265260B (en) pharmaceutical preparations
EP3434285A4 (en) PHARMACEUTICAL COMPOSITION AND USES THEREOF
IL262654A (en) Pharmacy preparation
IL265349A (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
HK1245113A1 (zh) 藥物組合物及其用途
IL257621B (en) A catechol derivative and a pharmaceutical preparation that includes it
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
ZA201903341B (en) Pharmaceutical compositions and uses thereof
IL265428A (en) Pharmaceutical composition
PT3476391T (pt) Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq
GB201620515D0 (en) Pharmaceutical composition
GB201620519D0 (en) Pharmaceutical composition
GB201620517D0 (en) Pharmaceutical composition